Search PubMed⌕ Search

Biomedical subjects

M Savage

Publications and source records attributed to M Savage.

84 records · Page 5Linked to original sources

A mutant of Escherichia coli defective in leucyl, phenylalanyl-tRNA-protein transferase.

A mutant of E. coli that lacks leucyl,-phenylalanyl-tRNA-protein transferase (EC 2.3.2.6) has been isolated. Ability to produce the two activities could be introduced into the mutant from an F' strain whose episome contains genetic material located between 45 and 54 min on the E. coli chromosome. When grown into stationary phase and resuspended in minimal medium with glycerol, the mutant exhibited a marked lag before resuming growth. Revertants that did not show this lag were selected and were found to have regained both transfer activities. Extracts of wild-type, mutant, and revertant strains were compared as acceptors for the enzymatic transfer of radioactive phenylalanine. Analysis of the labeled polypeptides by disc gel electrophoresis indicated that certain potential acceptors may be preferentially acylated in vivo. These data provide genetic confirmation that the same enzyme protein catalyzes the transfer of leucine and phenylalanine and suggest that leucyl,phenylalanyl-tRNA-protein transferase is involved in a growth regulatory mechanism.

Acyltransferases↗

Adherence to clinical guidance in the prescribing of oral antithrombotic medication in patients with atrial fibrillation.

BACKGROUND: Atrial fibrillation is the commonest cardiac rhythm disturbance and is an independent risk factor for stroke; however, use of oral antithrombotic therapy is reported to be suboptimal in clinical practice. AIM: The aim of the study was to evaluate the prescribing rates of oral antithrombotic therapy in patients with atrial fibrillation to determine if prescribing patterns reflected published clinical guidance. METHOD: Patients with atrial fibrillation, admitted to hospital over a 12-week period were identified and their antithrombotic therapy regimen was analysed using statistical methods. RESULTS: Although 87/100 patients identified were prescribed OAT, the regimen was suboptimal in 35 patients. Patients aged 75 years and older were more likelyto be receiving suboptimal oral antithrombotic treatment compared with younger patients CONCLUSIONS: The benefits and suitability of oral antithrombotic therapy for patients of all ages need to be more comprehensively communicated to prescribers.

Aged↗